The current malarial treatments are based on artemisinin with lumefantrine. But there were recent reports of increased resistance of parasites to artemisinin.
World's First Malaria Vaccine to be Rolled Out to Children in Sub-Saharan Africa
WHO panel said the Mosquirix vaccine should be given in three to five different areas with moderate-to-high malaria transmission, before considering wider use.
WHO panel said the Mosquirix vaccine should be given in three to five different areas with moderate-to-high malaria transmission, before considering wider use.
‘Malaria affects millions of people across the world and still scientists are working on effective treatments to combat the disease. Eisai also aims to fulfill this dream by creating novel antimalarial compounds to prevent its transmission.’
Most of the current malarial treatments are based on the rapidly-acting artemisinin with lumefantrine. But there were recent reports of increased resistance of malarial parasites to artemisinin. Therefore, scientists are focusing to develop a Single Exposure Radical Cure and Prophylaxis (SERCaP), a single dose drug that would cure patients after one exposure and provide substantial post-treatment protection from relapse as well as block transmission to mosquitoes. Eisai’s first agreement is a joint development program with the Liverpool School of Tropical Medicine (Location: Liverpool, U.K.) and the University of Liverpool (Location: Liverpool, U.K.). These three jointly focus on conducting preclinical trials of a compound called E209, which showed increased efficacy against artemisinin- resistant malarial parasites.
The second agreement is a joint development program with the non-profit public-private product development partnership Medicines for Malaria Venture (MMV). Eisai and MMV aim to ultimately identify antimalarial candidate compounds with novel mechanisms of action that will be effective against malaria parasites resistant to existing treatments, as well as prevent relapse and block transmission to mosquitoes. This involves the optimization of compounds developed by Eisai that inhibit the biosynthesis of glycosylphosphatidylinositol (GPI) necessary for the growth of malaria parasites.
Relapsing Infections can Prove to be Problematic for Malaria Eradication
The research showed relapsing infections with P. vivax were responsible for 80% of infections in children aged five to 10 years.
The research showed relapsing infections with P. vivax were responsible for 80% of infections in children aged five to 10 years.
Source-Medindia
Drug-Resistant Malaria Parasite from Southeast Asia Could Spread to Africa
The artemisinin-resistant malaria parasite has not yet been documented in Africa, but has been spreading rapidly through southeast Asia.
The artemisinin-resistant malaria parasite has not yet been documented in Africa, but has been spreading rapidly through southeast Asia.
Nobel Malaria Drug 'Artemisinin' Has Roots in India
An Indian scientist has fueled a debate for the discovery of artemisinin, extracted from a medicinal plant called artemisia annua and used in malaria therapy.
An Indian scientist has fueled a debate for the discovery of artemisinin, extracted from a medicinal plant called artemisia annua and used in malaria therapy.
